CME Information

Fourth International Workshop on the Biology, Prevention, And Treatment of Relapse after Hematopoietic Stem Cell Transplantation
InterContinental Chicago
September 21-22, 2018

DESCRIPTION

Relapse and disease progression are the leading causes of treatment failure for most hematologic malignancies treated with both allogeneic and autologous hematopoietic stem cell transplantation (HSCT). This symposium continues to grow and evolve from achievements of the first three Workshops, as we have witnessed tremendous progress in our understanding and treatment of relapse in the past 12 years. As such, the planned objectives of the fourth workshop are designed to present the latest scientific and clinical advances related to relapse after HSCT and to provide a forum for the presentation of ongoing laboratory, translational, and clinical research specifically related to this field.

The workshop will feature internationally-recognized speakers from a multidisciplinary, diverse group comprised of basic and translational scientists and clinical investigators. The Workshop will include formal didactic presentations and informal discussion panels. It will also offer investigators interested in the field the opportunity to present their work in dedicated oral and poster sessions.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

- Update the current state of the science relative to biology and clinical study of relapse related to both autologous and allogeneic HSCT;
- Provide a forum for the presentation of ongoing laboratory and translational research specifically related to relapse following HSCT;
- Provide a forum to present ongoing clinical trials that are specific to the study of and treatment of relapse following HSCT;
- Provide an overview of the potential role of CAR T-cells and other cellular therapies in the prevention and treatment of relapse following HSCT.

TARGET AUDIENCE

This activity has been designed for medical and pediatric hematologists-oncologists, hematopoietic stem and immune cell translational and basic scientists, hematopathologists, physicians-in-training (Fellows/Residents/Post Docs), advance practice providers, pharmacists, oncology nurses and other associated allied health professionals.

ACCREDITATION AND CREDIT DESIGNATION

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and the Organizing Committee. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine MOC II Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other Healthcare Professions Credit

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

European Union of Medical Specialties

The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS). International physicians interested in converting AMA PRA Category 1 Credit™ to EACCME credit should contact the UEMS.

EDUCATIONAL GRANTS/COMMERCIAL SUPPORT

Educational grant funding has been generously provided by:

-Celgene
-Kite Pharma, Inc.
-Novartis
-Pfizer Inc.
-Seattle Genetics

Sponsorship has been generously provided by:

-Novartis: Platinum Sponsor
-Amgen Inc.: Silver Sponsor
-Pfizer Oncology: Breakfast Symposium

Classic Sponsors:

-Abbvie Inc.
-Kite Pharma, Inc.
-Jazz Pharmaceuticals
- Merck & Co. Inc.
-Miltenyi Biotec
-Pharmacyclics
-Sanofi Genzyme
-Seattle Genetics
-Spectrum Pharmaceuticals
-Takeda Oncology

Additional sponsorship support has been generously provided by:

-Agios Pharmaceuticals Inc.
-American Society for Blood and Marrow Transplantation
-Astellas Pharma Inc.
-Bayer

DISCLOSURE DECLARATIONS

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

COURSE FACULTY

The following individuals have disclosed no relevant financial relationships:

Peter Dreger, MD
Terry Fry, MD
Luca Gattinoni, MD
Boglarka Gyurkocza, MD
Xiaojun Huang, MD, PhD
Krishna Komanduri, MD
Swati Naik, MD
Brian Parkin, MD
Steven Pavletic, MD, MS
Hans Schreiber, MD, DMSc, PhD
Nirali Shah, MD, MHSc
Haneen Shalabi, DO
Monica Thakar, MD

David Avigan, MD has served as a consultant for Takeda, Janssen, and Parexel. He has also served on the scientific advisory boards of Celgene and BMS and has received research funding from Pharmacyclics.

Veronika Bachanova, MD, PhD has served as a consultant for Kite, and GT Biopharma. She has also received research support from Novartis, GT Biopharma, Gamida, and UNUM.

Peter Bader, MD has served as a consultant for Novartis, Celgene, Amgen, and Medac. He has also served on the speaker's bureau for Novartis and Amgen and received research support from Riemser, Medac, and Neovii. Dr. Bader has received honoraria from Novartis and Amgen.

Juliet Barker, MBBS, FRACP has served as a consultant and researcher for Gamida Cell, and Angiocrine. She has also served as a consultant for NOHLA. She will discuss the unapproved/investigational use of CB expansion technologies currently under investigation. No results of any specific technology will be mentioned.

Michael Bishop, MD has served as a consultant for Novartis, Kite/Gilead, Juno, Celgene, and CRISPR. He is also on the speaker's bureau for Celgene and Kite/Gilead.

Ivan Borrello, MD has served as a consultant for WindMIL Therapeutics, Celgene, BMS, and Takeda. He has received research support from Celgene, BMS, and WindMIL Therapeutics. Dr. Borrello is a shareholder in WindMIL Therapeutics and has received honoraria from Celgene, BMS, and Takeda.

Jennifer Brudno, MD will discuss the investigational/unapproved use of CAR T-cell infusion in a clinical trial context.

Charles Craddock, MD, PhD has received research funding and honoraria from Celgene and Jazz, and has received honoraria from Janssen.

Marcos de Lima, MD has served as a consultant for Celgene, Pfizer, and Pharmacyclics and also received research support from Celgene. He will discuss the off-label use and/or investigational use of several pharmacologic agents after allogeneic transplantation for AML or MDS.

John DiPersio, MD, PhD has served on the consulting/Aavisory committees of Cellworks, Arch Pharma, Rivervest, BiolineRx, Asterias, Amphivena, Bluebird, and Incyte. Dr. DiPersio has ownership investment in Magenta and WUGEN.

Tim Fenske, MD has served as a consultant for Genentech, Seattle Genetics, Adaptive Biotechnologies. Dr. Fenske has served as an unbranded speaker for Sanofi, Celgene, and Astrazeneca. He will discuss the off-label use/ investigational use of Ibrutinib maintence after autoHCT for DLBCL.

Tom Gajewki, MD, PhD has served on the consultant/advisory boards of Roche-Genentech, Merck, Abbvie, Bayer, Aduro, Fog Pharma, Adaptimmune, and FivePrime. Dr. Gajewki has also received research support from Roche-Genentech, BMS, Merck, Incyte, Seattle Genetics, Celldex, Ono, Evelo, Bayer, and Aduro. He is a cofounder/shareholder of Jounce.

Sergio Giralt, MD has served as a consultant for: Amgen, Celgene, Johnson & Johnson, Takeda, Kite, Sanofi, Novartis, Spectrum, Actinuum. Dr. Giralt has also received research support from Amgen, Celgene, Takeda, Johnson & Johnson, Sanofi, Miltenyi, Spectrum, and Actinuum. He will discuss the off-label use and/or investigational use of various drugs in the context of hematopoietic cell transplantation.

Mehdi Hamadani, MD has served as a consultant for Cellerant Therapeutics, MedImmune, Celgene and Janssen. Dr. Harnadani has also received research support from Takeda, Otsuka, Spectrum, Sanofi, and served on the speaker's bureau of Otsuka, Celgene, and Sanofi.

Alex Herrera, MD has served as a consultant for: Bristol-Myers Squibb, Kite Pharma, Merck, Genentech, and Seattle Genetics. Dr. Herrera has received grant/research support from: Bristol-Myers Squibb, Kite Pharma, Merck, Genentech, Seattle Genetics, AstraZeneca, Pharmacyclics, and ImmuneDesign. He will discuss the following off label use and/or investigational use of Rituximab.

Mary Horowitz, MD, MS has received research/Educational Support of the CIBMTR from Astellas, Biovitrum, Bluebird Bio, Bristol-Myers Squibb, **Celgene**, Gamida, GlaxoSmithKline, Incyte Corporation, Jazz Pharmaceuticals, **Kite Pharma/Gilead**, Magenta, Merck, **Novartis**, Otsuka, Pfizer, Sanofi, Seattle Genetics, Shire Pharmaceuticals, and Takeda with funding from those in bold directly related to development of a Cellular Therapy Registry.

Stephen Hunger, MD has served as a consultant for Novartis and is a shareholder of Amgen and Merck.

John Koreth, MBBS, DPhil has received research support from Millennium, Otsuka, Miltenyi, BMS, and Prometheus. He has served as a consultant for Amgen and Equilium and on the advisory boards of Millennium and Takeda. He will discuss the off label/investigational use of various BMT regimens, which are all non-FDA approved though routinely used.

Nicolaus Kroeger, MD will discuss the off label/investigational use of lenalidomide post allogeneic SCT, Daratumumab post allogeneic SCT and Thalidomide post allogeneic SCT.

Ola Landgren, MD, PhD has received grant support from NIH, FDA, MMRF, IMF, LLS, Perelman Family Foundation, Rising Tides Foundation, Amgen, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm. Dr. Landgren has received honoraria/ad boards from Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer. Dr. Landgren is chairman for "Medscape myeloma": 2014-ongoing and on the Independent Data Monitoring Committee (IDMC) for Takeda, Novartis, and Janssen.

Marcela Maus, MD, PhD has served as a consultant for Adaptimmune, Adaptive Biotechnologies, Agentus, Bluebird Bio, Cellectis (SAB), CRISPR therapeutics, Incysus, Kite Pharma, Juno, Novartis, TCR2 (SAB), Third Rock Ventures, and WindMIL (SAB). Dr. Maus has received grant/research support from: Agentus, CRISPR therapeutics, and TCR2. Dr. Maus may discuss the following off label use and/or investigational use: CTL019, CART-BCMA, bb2121.

Richard Maziarz, MD has served as a consultant for Novartis, Incyte, CRISPR Therapeutics, and Athersys. Dr. Maziarz has received Grant/Research support from Novartis and Juno. He has received honoraria from Incyte, Kite Therapeutics; and Juno.

Philip McCarthy, MD has served as a consultant for Bristol-Myers Squibb, Celgene, Janssen, Karyopharm, Takeda, Amgen, and Sanofi, The Binding Site, and Magenta Therapeutics. Dr. McCarthy has received honoraria from Bristol-Myers Squibb, Celgene, Janssen, Karyopharm, Takeda, Amgen, Sanofi, and The Binding Site. Dr. McCarthy will discuss the off-label use and/or investigational use of different consolidation and maintenance strategies after autologous hematopoietic stem cell transplant for multiple myeloma and the use of minimal residual disease testing and immune profiling to predict outcome.

Sattva Neelapu, MD has received research support from Kite, Merck, BMS, Cellectis, Poseida, Karus, and Acerta. Dr. Neelapu has served as an advisory board member / consultant for Kite, Merck, Celgene, Novartis, Unum Therapeutics, and Pfizer. Dr. Neelapu will discuss investigational use of CAR T-cell therapy.

Michael Pulsipher, MD is a member of a steering committee that guides conduct of the Novartis 2205J and 2202 studies of CTL019 CAR T-cells and is paid an hourly fee for time, <10hrs/yr. Dr. Pulsipher has performed advisory and educational activities for Chimerix, Jazz, Novartis, Incyte, Amgen and Medac Pharmaceuticals. He will discuss the use of immune- and cell-based therapies that are currently not FDA approved.

Noopur Raje, MD has served as a consultant/advisory board of Celgene, Millenium, Takeda, Amgen-Onyx, Novartis, Janssen, BMS, Merck, and Bluebird. Dr. Raje has received research funding from AstraZeneca and has served on the steering committee for Amgen and Roche.

Alessandro Rambaldi, MD has served as a consultant Roche, Amgen, Novartis, Pfizer, Italfarmaco, Celgene, and Omeros.

Stanley Riddell, MD has served as founder, consultant, and researcher for Juno/Celgene. He has also served as a consultant for NOHLA, Adaptive Biotechnologies, and Cell Medica. He will discuss the investigational/unapproved use of CAR T cells.

Christoph Schmid, MD has served on the speaker's bureau for Novartis and also received travel grants from Novartis

Christian Steidl, MD has served on the advisory board for Affirmed Therapeutics and has consulted for Seattle Genetics and Roche. Dr. Steidl has provided expert testimony for Juno Therapeutics and Sloan Kettering Cancer Center. He has also received research funding from BMS and Tioma.
Luca Vago, MD, PhD has received grant/research support from GEN-DX B.V. and Moderna Therapeutics. Dr. Vago will discuss the off-label/investigational use of HLA-KMR, GEN-DX.

Marcel van den Brink, MD, PhD has served as a consultant for Seres Therapeutics and has received grant/research support from NIA, NHLBI, NCI, NIAID, PICI, The Susan and Peter Solomon Divisional Genomics Fund, Tri-Institutional Stem Cell Initiative, and The Lymphoma Foundation. He has IP Licensing from Seres Therapeutics, and Juno Therapeutics. He has received honoraria from Merck & Co Inc, Flagship Ventures, Novartis, Evelo, Seres, Jazz Pharmaceuticals, Therakos, and Amgen.

Alan Wayne, MD has received grant/research support from Spectrum Pharmaceuticals, Institut de Recherches Internationales Servier (Servier / I.R.I.S.), and Kite Pharma. Dr. Wayne has served as a consultant for AbbVie and is a co-inventor on investigational products with patents assigned to the NIH. Dr. Wayne will discuss the off-label use and/or investigational use of CAR T cell products for acute lymphoblastic leukemia.

John Welch, MD, PhD has served as a consultant for Rigel Pharmaceuticals and has received grant/research support from Janssen Pharmaceuticals. He will discuss the off-label/investigational use of Decitabine and lenalidominde for AML.

UNIVERSITY OF CHICAGO CENTER FOR CONTINUING MEDICAL EDUCATION AND MOC&CO

The staff of the Center for Continuing Medical Education and MOC&CO have no financial relationships to disclose.

DISCLAIMER

The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.